RightFit
RecruitingPhase 4

A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Topical-Lingual Semaglutide (T-L Semaglutide) in Adults With Obesity

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 65 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests semaglutide as a liquid placed on the tongue in adults with obesity. Semaglutide acts like a gut hormone that helps people feel full. The study explores whether this way of giving hormones can work.

This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Body mass index (BMI) of 30 to 45. BMI is a measure of weight compared with height.

Who can't join

  • Type 2 diabetes, a condition that causes high blood sugar.
  • Multiple endocrine neoplasia type 2, a condition that causes tumors in glands that make hormones.
  • Medullary thyroid cancer, a type of cancer in the thyroid gland in the neck.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Body Mass Index 30 to 45 Exclusion Criteria: * Type 2 Diabetes Mellitus * Multiple Endocrine Neoplasia Type 2 * Medullary thyroid cancer

Study sites (1)

MN